According to the company, the patent will provide exclusivity for Pulmaquin until 22 October 2027.
Pulmaquin is a dual release formulation that is a mixture of a liposomal formulation of ciprofloxacin with unencapsulated ciprofloxacin.
Ciprofloxacin is an antibiotic to treat infections of the lung frequently experienced by cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE) patients.
The drug candidate demonstrated superior performance in clinical study that assesses two different formulations of inhaled ciprofloxacin (ARD-3100 – Lipoquin and ARD-3150 – Pulmaquin).
Aradigm intends to take Pulmaquin forward into Phase 3 clinical trials.